Literature DB >> 15978223

Symptom scores: mumbo jumbo or meaningful measures?

A Christopher Stage1, John C Hairston.   

Abstract

Instruments designed to assess the severity of lower urinary tract symptoms have become a routine component of the diagnostic evaluation of men with benign prostatic hyperplasia (BPH). Several validated tools have been developed to this end, including the International Prostate Symptom Score, which is used most commonly today. Despite attempts to correlate symptom score severity with commonly measured objective parameters of BPH, no clear relationships have been found. The reason for this is likely multifactorial and suggests a complex relationship among subjective and objective variables. However, symptom scores show a good correlation with the patient's perception of quality of life and degree of bother. This is critical because the decision to treat should be largely based on these subjective variables. Moreover, symptom scores have been shown to represent a meaningful endpoint in assessing treatment response in clinical studies.

Entities:  

Mesh:

Year:  2005        PMID: 15978223     DOI: 10.1007/s11934-005-0017-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  32 in total

1.  A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia.

Authors:  T Hald; J Nordling; J T Andersen; T Bilde; H H Meyhoff; S Walter
Journal:  Scand J Urol Nephrol Suppl       Date:  1991

2.  Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Authors:  M D Eckhardt; G E van Venrooij; T A Boon
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

3.  Serial residual volumes in men with prostatic hypertrophy.

Authors:  N C Birch; G Hurst; P T Doyle
Journal:  Br J Urol       Date:  1988-12

4.  Scoring the short form ICSmaleSF questionnaire. International Continence Society.

Authors:  J L Donovan; T J Peters; P Abrams; S T Brookes; J J de aa Rosette; W Schäfer
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

5.  The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms.

Authors:  T J Peters; J L Donovan; H E Kay; P Abrams; J J de la Rosette; D Porru; J W Thüroff
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

6.  Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.

Authors:  B J Hansen; H Flyger; K Brasso; J Schou; J Nordling; J Thorup Andersen; S Mortensen; H H Meyhoff; S Walter; T Hald
Journal:  Br J Urol       Date:  1995-10

7.  The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction.

Authors:  J M Reynard; Q Yang; J L Donovan; T J Peters; W Schafer; J J de la Rosette; N F Dabhoiwala; D Osawa; A T Lim; P Abrams
Journal:  Br J Urol       Date:  1998-11

8.  Hard measures of subjective outcomes: validating symptom indexes in urology.

Authors:  M P O'Leary; M J Barry; F J Fowler
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

9.  Mode of administration of international prostate symptom score in patients with lower urinary tract symptoms: physician vs self.

Authors:  K Cam; Y Akman; B Cicekci; F Senel; A Erol
Journal:  Prostate Cancer Prostatic Dis       Date:  2004       Impact factor: 5.554

10.  Symptom status and quality of life following prostatectomy.

Authors:  F J Fowler; J E Wennberg; R P Timothy; M J Barry; A G Mulley; D Hanley
Journal:  JAMA       Date:  1988-05-27       Impact factor: 56.272

View more
  3 in total

1.  Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study.

Authors:  Dany-Jan Yassin; Yousef El Douaihy; Aksam A Yassin; James Kashanian; Ridwan Shabsigh; Peter G Hammerer
Journal:  World J Urol       Date:  2013-10-18       Impact factor: 4.226

2.  Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.

Authors:  Mallik Angalakuditi; Rita F Seifert; Risa P Hayes; Michael P O'Leary; Lars Viktrup
Journal:  Health Qual Life Outcomes       Date:  2010-11-12       Impact factor: 3.186

3.  Correlation of tools for objective evaluation of infravesical obstruction of men with lower urinary tract symptoms.

Authors:  Orestes Mazzariol; Leonardo O Reis; Paulo R Palma
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.